Imaging of Soft Tissue Tumors

Shinji       Tsukamoto; Andreas    F.    Mavrogenis; Yasuhito       Tanaka; Costantino       Errani
Abstract

Differentiation of malignant from benign soft tissue tumors is challenging with imaging alone, including that by magnetic resonance imaging and computed tomography. However, the accuracy of this differentiation has increased owing to the development of novel imaging technology. Detailed patient history and physical examination remain essential for differentiation between benign and malignant soft tissue tumors. Moreover, measurement only of tumor size based on Response Evaluation Criteria In Solid Tumors criteria is insufficient for the evaluation of response to chemotherapy or radiotherapy. Change in metabolic activity measured by ¹⁸F-fluorodeoxyglucose positron emission tomography or dynamic contrast enhanced-derived quantitative endpoints can more accurately evaluate treatment response compared to change in tumor size. Magnetic resonance imaging can accurately evaluate essential factors in surgical planning such as vascular or bone invasion and “tail sign”. Thus, imaging plays a critical role in the diagnosis and treatment of soft tissue tumors.
Keywords: Imaging, soft tissue tumor, sarcoma, CT, MRI, PET.
Graphical Abstract

[1] 
Colman MW, Lozano-Calderon S, Raskin KA, Hornicek FJ, Gebhardt M. Non-neoplastic soft tissue masses that mimic sarcoma. Orthop Clin North Am  2014; 45(2): 245-55.
[http://dx.doi.org/10.1016/j.ocl.2013.12.006] [PMID: 24684918] 
[2] 
Mayerson JL, Scharschmidt TJ, Lewis VO, Morris CD. Diagnosis and management of soft-tissue masses. J Am Acad Orthop Surg  2014; 22(11): 742-50.
[http://dx.doi.org/10.5435/JAAOS-22-11-742] [PMID: 25344599] 
[3] 
Colleran G, Madewell J, Foran P, Shelly M, O’Sullivan PJ. Imaging of soft tissue and osseous sarcomas of the extremities. Semin Ultrasound CT MR  2011; 32(5): 442-55.
[http://dx.doi.org/10.1053/j.sult.2011.05.001] [PMID: 21963165] 
[4] 
Eary JF, Conrad EU. Imaging in sarcoma. J Nucl Med  2011; 52(12): 1903-13.
[http://dx.doi.org/10.2967/jnumed.111.092999] [PMID: 22052127] 
[5] 
Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl  1994; 259: 1-31.
[PMID: 8042499] 
[6] 
Wu JS, Hochman MG. Soft-tissue tumors and tumorlike lesions: A systematic imaging approach. Radiology  2009; 253(2): 297-316.
[http://dx.doi.org/10.1148/radiol.2532081199] [PMID: 19864525] 
[7] 
Cates JMM. AJCC eighth edition for soft tissue sarcoma of the extremities and trunk Ann Oncol  2018; 29(9): 2023.
[8] 
Pham K, Ezuddin NS, Pretell-Mazzini J, Subhawong TK. Small soft tissue masses indeterminate at imaging: histological diagnoses at a tertiary orthopedic oncology clinic. Skeletal Radiol  2019; 48(10): 1555-63.
[http://dx.doi.org/10.1007/s00256-019-03205-0] [PMID: 30903259] 
[9] 
Smolle MA, Andreou D, Tunn P-U, Szkandera J, Liegl-Atzwanger B, Leithner A. Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk. EFORT Open Rev  2017; 2(10): 421-31.
[http://dx.doi.org/10.1302/2058-5241.2.170005] [PMID: 29209518] 
[10] 
Crawford EA, Slotcavage RL, King JJ, Lackman RD, Ogilvie CM. Ethanol sclerotherapy reduces pain in symptomatic musculoskeletal hemangiomas. Clin Orthop Relat Res  2009; 467(11): 2955-61.
[http://dx.doi.org/10.1007/s11999-009-0919-2] [PMID: 19536604] 
[11] 
Setsu N, Kohashi K, Fushimi F, et al. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma. Cancer  2013; 119(19): 3504-13.
[http://dx.doi.org/10.1002/cncr.28255] [PMID: 23861137] 
[12] 
Endo M, Yamamoto H, Harimaya K, et al. Conventional spindle cell-type malignant peripheral nerve sheath tumor arising in a sporadic schwannoma. Hum Pathol  2013; 44(12): 2845-8.
[http://dx.doi.org/10.1016/j.humpath.2013.05.021] [PMID: 24007690] 
[13] 
Endo M, Kobayashi C, Setsu N, et al. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res  2011; 17(11): 3771-82.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-2393] [PMID: 21262917] 
[14] 
Endo M, Yamamoto H, Setsu N, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res  2013; 19(2): 450-61.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-1067] [PMID: 23209032] 
[15] 
Widemann BC, Acosta MT, Ammoun S, et al. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A  2014; 164A(3): 563-78.
[http://dx.doi.org/10.1002/ajmg.a.36312] [PMID: 24443315] 
[16] 
Hogg ME, Wayne JD. Atypical lipomatous tumor/well-differentiated liposarcoma: what is it? Surg Oncol Clin N Am  2012; 21(2): 333-40.
[http://dx.doi.org/10.1016/j.soc.2011.12.007] [PMID: 22365523] 
[17] 
Endo M, Oda Y, Harimaya K, et al. Low-grade dedifferentiated liposarcoma of the neck: Magnetic resonance imaging and pathological correlation. J Orthop Sci  2010; 15(1): 148-52.
[http://dx.doi.org/10.1007/s00776-009-1407-y] [PMID: 20151266] 
[18] 
Noebauer-Huhmann IM, Weber M-A, Lalam RK, et al. Soft tissue tumors in adults: ESSR-approved guidelines for diagnostic imaging. Semin Musculoskelet Radiol  2015; 19(5): e1.
[PMID: 26841322] 
[19] 
Wilkerson BW, Crim JR, Hung M, Layfield LJ. Characterization of synovial sarcoma calcification. AJR Am J Roentgenol  2012; 199(6): W730-4.
[http://dx.doi.org/10.2214/AJR.11.7342] [PMID: 23169746] 
[20] 
Mc Auley G, Jagannathan J, O’Regan K, et al. Extraskeletal osteosarcoma: Spectrum of imaging findings. AJR Am J Roentgenol  2012; 198(1): W31-7.
[http://dx.doi.org/10.2214/AJR.11.6927] [PMID: 22194512] 
[21] 
Amini B, Jessop AC, Ganeshan DM, Tseng WW, Madewell JE. Contemporary imaging of soft tissue sarcomas. J Surg Oncol  2015; 111(5): 496-503.
[http://dx.doi.org/10.1002/jso.23801] [PMID: 25348367] 
[22] 
Tzeng C-WD, Smith JK, Heslin MJ. Soft tissue sarcoma: preoperative and postoperative imaging for staging. Surg Oncol Clin N Am  2007; 16(2): 389-402.
[http://dx.doi.org/10.1016/j.soc.2007.03.006] [PMID: 17560519] 
[23] 
Gruber L, Gruber H, Luger AK, Glodny B, Henninger B, Loizides A. Diagnostic hierarchy of radiological features in soft tissue tumours and proposition of a simple diagnostic algorithm to estimate malignant potential of an unknown mass. Eur J Radiol  2017; 95: 102-10.
[http://dx.doi.org/10.1016/j.ejrad.2017.07.020] [PMID: 28987653] 
[24] 
Beltran J, Simon DC, Katz W, Weis LD. Increased MR signal intensity in skeletal muscle adjacent to malignant tumors: Pathologic correlation and clinical relevance. Radiology  1987; 162(1 Pt 1): 251-5.
[http://dx.doi.org/10.1148/radiology.162.1.3786772] [PMID: 3786772] 
[25] 
Bhargava R, Parham DM, Lasater OE, Chari RS, Chen G, Fletcher BD. MR imaging differentiation of benign and malignant peripheral nerve sheath tumors: Use of the target sign. Pediatr Radiol  1997; 27(2): 124-9.
[http://dx.doi.org/10.1007/s002470050082] [PMID: 9028843] 
[26] 
Berquist TH, Ehman RL, King BF, Hodgman CG, Ilstrup DM. Value of MR imaging in differentiating benign from malignant soft-tissue masses: Study of 95 lesions. AJR Am J Roentgenol  1990; 155(6): 1251-5.
[http://dx.doi.org/10.2214/ajr.155.6.2122675] [PMID: 2122675] 
[27] 
Crim JR, Seeger LL, Yao L, Chandnani V, Eckardt JJ. Diagnosis of soft-tissue masses with MR imaging: Can benign masses be differentiated from malignant ones? Radiology  1992; 185(2): 581-6.
[http://dx.doi.org/10.1148/radiology.185.2.1410377] [PMID: 1410377] 
[28] 
Gielen JLMA, De Schepper AM, Vanhoenacker F, et al. Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients. Eur Radiol  2004; 14(12): 2320-30.
[http://dx.doi.org/10.1007/s00330-004-2431-0] [PMID: 15290067] 
[29] 
Myhre-Jensen O. A consecutive 7-year series of 1331 benign soft tissue tumours. Clinicopathologic data. Comparison with sarcomas. Acta Orthop Scand  1981; 52(3): 287-93.
[http://dx.doi.org/10.3109/17453678109050105] [PMID: 7282321] 
[30] 
Kransdorf MJ, Jelinek JS, Moser RP Jr, et al. Soft-tissue masses: diagnosis using MR imaging. AJR Am J Roentgenol  1989; 153(3): 541-7.
[http://dx.doi.org/10.2214/ajr.153.3.541] [PMID: 2763953] 
[31] 
Papp DF, Khanna AJ, McCarthy EF, Carrino JA, Farber AJ, Frassica FJ. Magnetic resonance imaging of soft-tissue tumors: determinate and indeterminate lesions. J Bone Joint Surg Am  2007; 89(Suppl. 3): 103-15.
[PMID: 17908876] 
[32] 
Lang P, Honda G, Roberts T, et al. Musculoskeletal neoplasm: perineoplastic edema versus tumor on dynamic postcontrast MR images with spatial mapping of instantaneous enhancement rates. Radiology  1995; 197(3): 831-9.
[http://dx.doi.org/10.1148/radiology.197.3.7480764] [PMID: 7480764] 
[33] 
Engellau J, Bendahl P-O, Persson A, et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol  2005; 36(9): 994-1002.
[http://dx.doi.org/10.1016/j.humpath.2005.07.008] [PMID: 16153463] 
[34] 
Fernebro J, Wiklund M, Jonsson K, et al. Focus on the tumour periphery in MRI evaluation of soft tissue sarcoma: Infiltrative growth signifies poor prognosis. Sarcoma  2006; 2006: 21251.
[http://dx.doi.org/10.1155/SRCM/2006/21251] [PMID: 17496992] 
[35] 
Zhao F, Ahlawat S, Farahani SJ, et al. Can MR imaging be used to predict tumor grade in soft-tissue sarcoma? Radiology  2014; 272(1): 192-201.
[http://dx.doi.org/10.1148/radiol.14131871] [PMID: 24611604] 
[36] 
Ahlawat S, Fayad LM. Imaging cellularity in benign and malignant peripheral nerve sheath tumors: Utility of the “target sign” by diffusion weighted imaging. Eur J Radiol  2018; 102: 195-201.
[http://dx.doi.org/10.1016/j.ejrad.2018.03.018] [PMID: 29685535] 
[37] 
Galant J, Martí-Bonmatí L, Soler R, et al. Grading of subcutaneous soft tissue tumors by means of their relationship with the superficial fascia on MR imaging. Skeletal Radiol  1998; 27(12): 657-63.
[http://dx.doi.org/10.1007/s002560050455] [PMID: 9921926] 
[38] 
Gruber L, Loizides A, Luger AK, et al. Soft-tissue tumor contrast enhancement patterns: diagnostic value and comparison between ultrasound and MRI. AJR Am J Roentgenol  2017; 208(2): 393-401.
[http://dx.doi.org/10.2214/AJR.16.16859] [PMID: 27959625] 
[39] 
Stull MA, Moser RP Jr, Kransdorf MJ, Bogumill GP, Nelson MC. Magnetic resonance appearance of peripheral nerve sheath tumors. Skeletal Radiol  1991; 20(1): 9-14.
[http://dx.doi.org/10.1007/BF00243714] [PMID: 1900374] 
[40] 
Abreu E, Aubert S, Wavreille G, Gheno R, Canella C, Cotten A. Peripheral tumor and tumor-like neurogenic lesions. Eur J Radiol  2013; 82(1): 38-50.
[http://dx.doi.org/10.1016/j.ejrad.2011.04.036] [PMID: 21561733] 
[41] 
Murphey MD, Smith WS, Smith SE, Kransdorf MJ, Temple HT. From the archives of the AFIP. Imaging of musculoskeletal neurogenic tumors: radiologic-pathologic correlation. Radiographics  1999; 19(5): 1253-80.
[http://dx.doi.org/10.1148/radiographics.19.5.g99se101253] [PMID: 10489179] 
[42] 
Pilavaki M, Chourmouzi D, Kiziridou A, Skordalaki A, Zarampoukas T, Drevelengas A. Imaging of peripheral nerve sheath tumors with pathologic correlation: Pictorial review. Eur J Radiol  2004; 52(3): 229-39.
[http://dx.doi.org/10.1016/j.ejrad.2003.12.001] [PMID: 15544900] 
[43] 
Chee DWY, Peh WCG, Shek TWH. Pictorial essay: Imaging of peripheral nerve sheath tumours. Can Assoc Radiol J  2011; 62(3): 176-82.
[http://dx.doi.org/10.1016/j.carj.2010.04.009] [PMID: 20510574] 
[44] 
Sung J, Kim J-Y. Fatty rind of intramuscular soft-tissue tumors of the extremity: is it different from the split fat sign? Skeletal Radiol  2017; 46(5): 665-73.
[http://dx.doi.org/10.1007/s00256-017-2598-5] [PMID: 28255944] 
[45] 
Etchebehere EC, Hobbs BP, Milton DR, et al. Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging  2016; 43(5): 860-70.
[http://dx.doi.org/10.1007/s00259-015-3242-z] [PMID: 26631240] 
[46] 
Folpe AL, Lyles RH, Sprouse JT, Conrad EU III, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res  2000; 6(4): 1279-87.
[PMID: 10778952] 
[47] 
Tateishi U, Kawai A, Chuman H, et al. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med  2011; 36(7): 526-32.
[http://dx.doi.org/10.1097/RLU.0b013e3182175856] [PMID: 21637052] 
[48] 
Sambri A, Bianchi G, Longhi A, et al. The role of 18F-FDG PET/CT in soft tissue sarcoma. Nucl Med Commun  2019; 40(6): 626-31.
[http://dx.doi.org/10.1097/MNM.0000000000001002] [PMID: 30908341] 
[49] 
Buck AK, Herrmann K, Büschenfelde CMZ, et al. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Clin Cancer Res  2008; 14(10): 2970-7.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-4294] [PMID: 18445694] 
[50] 
Wieder HA, Pomykala KL, Benz MR, Buck AK, Herrmann K. PET tracers in musculoskeletal disease beyond FDG. Semin Musculoskelet Radiol  2014; 18(2): 123-32.
[http://dx.doi.org/10.1055/s-0034-1371015] [PMID: 24715445] 
[51] 
Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med  2000; 27(10): 1509-17.
[http://dx.doi.org/10.1007/s002590000344] [PMID: 11083540] 
[52] 
Steiner E, Steinbach LS, Schnarkowski P, Tirman PF, Genant HK. Ganglia and cysts around joints. Radiol Clin North Am  1996; 34(2): 395-425.
[PMID: 8633123] 
[53] 
McKenzie G, Raby N, Ritchie D. Pictorial review: Non-neoplastic soft-tissue masses. Br J Radiol  2009; 82(981): 775-85.
[http://dx.doi.org/10.1259/bjr/17870414] [PMID: 19064599] 
[54] 
Nuovo MA, Norman A, Chumas J, Ackerman LV. Myositis ossificans with atypical clinical, radiographic, or pathologic findings: a review of 23 cases. Skeletal Radiol  1992; 21(2): 87-101.
[http://dx.doi.org/10.1007/BF00241831] [PMID: 1566115] 
[55] 
Parikh J, Hyare H, Saifuddin A. The imaging features of post-traumatic myositis ossificans, with emphasis on MRI. Clin Radiol  2002; 57(12): 1058-66.
[http://dx.doi.org/10.1053/crad.2002.1120] [PMID: 12475528] 
[56] 
Lin J, Martel W. Cross-sectional imaging of peripheral nerve sheath tumors: characteristic signs on CT, MR imaging, and sonography. AJR Am J Roentgenol  2001; 176(1): 75-82.
[http://dx.doi.org/10.2214/ajr.176.1.1760075] [PMID: 11133542] 
[57] 
Nakazono T, White CS, Yamasaki F, et al. MRI findings of mediastinal neurogenic tumors. AJR Am J Roentgenol  2011; 197(4): W643-52.
[http://dx.doi.org/10.2214/AJR.10.6119] [PMID: 21940535] 
[58] 
Chang DW, Weber KL. Use of a vascularized fibula bone flap and intercalary allograft for diaphyseal reconstruction after resection of primary extremity bone sarcomas. Plast Reconstr Surg  2005; 116(7): 1918-25.
[http://dx.doi.org/10.1097/01.prs.0000189203.38204.d5] [PMID: 16327604] 
[59] 
Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg  1982; 69(3): 412-22.
[http://dx.doi.org/10.1097/00006534-198203000-00002] [PMID: 7063565] 
[60] 
Donnelly LF, Adams DM, Bisset GS III. Vascular malformations and hemangiomas: A practical approach in a multidisciplinary clinic. AJR Am J Roentgenol  2000; 174(3): 597-608.
[http://dx.doi.org/10.2214/ajr.174.3.1740597] [PMID: 10701595] 
[61] 
Murphey MD, Fairbairn KJ, Parman LM, Baxter KG, Parsa MB, Smith WS. From the archives of the AFIP. Musculoskeletal angiomatous lesions: Radiologic-pathologic correlation. Radiographics  1995; 15(4): 893-917.
[http://dx.doi.org/10.1148/radiographics.15.4.7569134] [PMID: 7569134] 
[62] 
Cohen EK, Kressel HY, Perosio T, et al. MR imaging of soft-tissue hemangiomas: Correlation with pathologic findings. AJR Am J Roentgenol  1988; 150(5): 1079-81.
[http://dx.doi.org/10.2214/ajr.150.5.1079] [PMID: 3258709] 
[63] 
Dubois J, Garel L, Grignon A, et al. Imaging of hemangiomas and vascular malformations in children. Acad Radiol  1998; 5(5): 390-400.
[http://dx.doi.org/10.1016/S1076-6332(98)80158-X] [PMID: 9597107] 
[64] 
Rimondi E, Rossi G, Bartalena T, Ciminari R, Alberghini M, Ruggieri P, et al. Percutaneous CT-guided biopsy of the musculoskeletal system: Results of 2027 cases Eur J Radiol  2011; 34-42.
[65] 
Mavrogenis AF, Rossi G, Calabrò T, Altimari G, Rimondi E, Ruggieri P. The role of embolization for hemangiomas. Musculoskelet Surg  2012; 96(2): 125-35.
[http://dx.doi.org/10.1007/s12306-012-0207-2] [PMID: 22684541] 
[66] 
Mavrogenis AF, Angelini A, Errani C, Rimondi E. How should musculoskeletal biopsies be performed? Orthopedics  2014; 37(9): 585-8.
[http://dx.doi.org/10.3928/01477447-20140825-03] [PMID: 25198351] 
[67] 
Rimondi E, Mavrogenis AF, Errani C, et al. Biopsy is not necessary for the diagnosis of soft tissue hemangiomas. Radiol Med (Torino)  2018; 123(7): 538-44.
[http://dx.doi.org/10.1007/s11547-018-0862-y] [PMID: 29476440] 
[68] 
Palmerini E, Staals EL, Maki RG, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer  2015; 51(2): 210-7.
[http://dx.doi.org/10.1016/j.ejca.2014.11.001] [PMID: 25465190] 
[69] 
De Schepper AM, Hogendoorn PCW, Bloem JL. Giant cell tumors of the tendon sheath may present radiologically as intrinsic osseous lesions. Eur Radiol  2007; 17(2): 499-502.
[http://dx.doi.org/10.1007/s00330-006-0320-4] [PMID: 16807700] 
[70] 
Wan JMC, Magarelli N, Peh WCG, Guglielmi G, Shek TWH. Imaging of giant cell tumour of the tendon sheath. Radiol Med (Torino)  2010; 115(1): 141-51.
[http://dx.doi.org/10.1007/s11547-010-0515-2] [PMID: 20077044] 
[71] 
Llauger J, Palmer J, Rosón N, Cremades R, Bagué S. Pigmented villonodular synovitis and giant cell tumors of the tendon sheath: radiologic and pathologic features. AJR Am J Roentgenol  1999; 172(4): 1087-91.
[http://dx.doi.org/10.2214/ajr.172.4.10587152] [PMID: 10587152] 
[72] 
Kransdorf MJ, Murphey MD. MR imaging of musculoskeletal tumors of the hand and wrist. Magn Reson Imaging Clin N Am  1995; 3(2): 327-44.
[PMID: 7553026] 
[73] 
De Beuckeleer L, De Schepper A, De Belder F, et al. Magnetic resonance imaging of localized giant cell tumour of the tendon sheath (MRI of localized GCTTS). Eur Radiol  1997; 7(2): 198-201.
[http://dx.doi.org/10.1007/s003300050134] [PMID: 9038114] 
[74] 
Bravo SM, Winalski CS, Weissman BN. Pigmented villonodular synovitis. Radiol Clin North Am  1996; 34(2): 311-326, x-xi.
[PMID: 8633118] 
[75] 
Murphey MD, Rhee JH, Lewis RB, Fanburg-Smith JC, Flemming DJ, Walker EA. Pigmented villonodular synovitis: radiologic-pathologic correlation. Radiographics  2008; 28(5): 1493-518.
[http://dx.doi.org/10.1148/rg.285085134] [PMID: 18794322] 
[76] 
Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of tumours of soft tissue and bone. Lyon: IARC 2013.
[77] 
Milgram JW. Synovial osteochondromatosis: A histopathological study of thirty cases. J Bone Joint Surg Am  1977; 59(6): 792-801.
[http://dx.doi.org/10.2106/00004623-197759060-00013] [PMID: 908703] 
[78] 
Llauger J, Palmer J, Rosón N, Bagué S, Camins A, Cremades R. Nonseptic monoarthritis: Imaging features with clinical and histopathologic correlation. Radiographics  2000; 20(Spec No): S263-78.
[http://dx.doi.org/10.1148/radiographics.20.suppl_1.g00oc13s263] [PMID: 11046178] 
[79] 
Narváez JA, Narváez J, Ortega R, De Lama E, Roca Y, Vidal N. Hypointense synovial lesions on T2-weighted images: differential diagnosis with pathologic correlation. AJR Am J Roentgenol  2003; 181(3): 761-9.
[http://dx.doi.org/10.2214/ajr.181.3.1810761] [PMID: 12933477] 
[80] 
Beaman FD, Kransdorf MJ, Andrews TR, Murphey MD, Arcara LK, Keeling JH. Superficial soft-tissue masses: analysis, diagnosis, and differential considerations. Radiographics  2007; 27(2): 509-23.
[http://dx.doi.org/10.1148/rg.272065082] [PMID: 17374866] 
[81] 
Teniola O, Wang KY, Wang W-L, Tseng WW, Amini B. Imaging of liposarcomas for clinicians: Characteristic features and differential considerations. J Surg Oncol  2018; 117(6): 1195-203.
[http://dx.doi.org/10.1002/jso.24949] [PMID: 29228461] 
[82] 
Kransdorf MJ, Bancroft LW, Peterson JJ, Murphey MD, Foster WC, Temple HT. Imaging of fatty tumors: Distinction of lipoma and well-differentiated liposarcoma. Radiology  2002; 224(1): 99-104.
[http://dx.doi.org/10.1148/radiol.2241011113] [PMID: 12091667] 
[83] 
Peterson JJ, Kransdorf MJ, Bancroft LW, O’Connor MI. Malignant fatty tumors: classification, clinical course, imaging appearance and treatment. Skeletal Radiol  2003; 32(9): 493-503.
[http://dx.doi.org/10.1007/s00256-003-0647-8] [PMID: 12802520] 
[84] 
Hosono M, Kobayashi H, Fujimoto R, et al. Septum-like structures in lipoma and liposarcoma: MR imaging and pathologic correlation. Skeletal Radiol  1997; 26(3): 150-4.
[http://dx.doi.org/10.1007/s002560050211] [PMID: 9108224] 
[85] 
Murphey MD, Arcara LK, Fanburg-Smith J. From the archives of the AFIP: imaging of musculoskeletal liposarcoma with radiologic-pathologic correlation. Radiographics  2005; 25(5): 1371-95.
[http://dx.doi.org/10.1148/rg.255055106] [PMID: 16160117] 
[86] 
Murphey MD, Carroll JF, Flemming DJ, Pope TL, Gannon FH, Kransdorf MJ. From the archives of the AFIP: benign musculoskeletal lipomatous lesions. Radiographics  2004; 24(5): 1433-66.
[http://dx.doi.org/10.1148/rg.245045120] [PMID: 15371618] 
[87] 
Ohguri T, Aoki T, Hisaoka M, et al. Differential diagnosis of benign peripheral lipoma from well-differentiated liposarcoma on MR imaging: Is comparison of margins and internal characteristics useful? AJR Am J Roentgenol  2003; 180(6): 1689-94.
[http://dx.doi.org/10.2214/ajr.180.6.1801689] [PMID: 12760945] 
[88] 
Bhosale P, Wang J, Varma D, et al. Can abdominal computed tomography imaging help accurately identify a dedifferentiated component in a well-differentiated liposarcoma? J Comput Assist Tomogr  2016; 40(6): 872-9.
[http://dx.doi.org/10.1097/RCT.0000000000000462] [PMID: 27454788] 
[89] 
Lu J, Qin Q, Zhan L-L, et al. Computed tomography manifestations of histologic subtypes of retroperitoneal liposarcoma. Asian Pac J Cancer Prev  2014; 15(15): 6041-6.
[http://dx.doi.org/10.7314/APJCP.2014.15.15.6041] [PMID: 25124571] 
[90] 
Fujii S, Kawawa Y, Horiguchi S, Kamata N, Kinoshita T, Ogawa T. Low-grade fibromyxoid sarcoma of the small bowel mesentery: computed tomography and magnetic resonance imaging findings. Radiat Med  2008; 26(4): 244-7.
[http://dx.doi.org/10.1007/s11604-007-0214-7] [PMID: 18509725] 
[91] 
Messiou C, Moskovic E, Vanel D, et al. Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. Eur J Surg Oncol  2017; 43(7): 1191-8.
[http://dx.doi.org/10.1016/j.ejso.2016.10.032] [PMID: 28057392] 
[92] 
Rajiah P, Sinha R, Cuevas C, Dubinsky TJ, Bush WH Jr, Kolokythas O. Imaging of uncommon retroperitoneal masses. Radiographics  2011; 31(4): 949-76.
[http://dx.doi.org/10.1148/rg.314095132] [PMID: 21768233] 
[93] 
Mussi C, Collini P, Miceli R, et al. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: A series of surgically treated patients at a single institution. Cancer  2008; 113(7): 1657-65.
[http://dx.doi.org/10.1002/cncr.23774] [PMID: 18704991] 
[94] 
Errani C, Cocchi S, Ali N, et al. recurrence after marginal excision for atypical lipomatous tumors versus lipomas of the extremities. Orthopedics  2016; 39(4): e610-4.
[http://dx.doi.org/10.3928/01477447-20160610-02] [PMID: 27322173] 
[95] 
Roberts CC, Kransdorf MJ, Beaman FD, et al. ACR Appropriateness Criteria Follow-Up of Malignant or Aggressive Musculoskeletal Tumors. J Am Coll Radiol  2016; 13(4): 389-400.
[http://dx.doi.org/10.1016/j.jacr.2015.12.019] [PMID: 26922595] 
[96] 
Munk PL, Sallomi DF, Janzen DL, et al. Malignant fibrous histiocytoma of soft tissue imaging with emphasis on MRI. J Comput Assist Tomogr  1998; 22(5): 819-26.
[http://dx.doi.org/10.1097/00004728-199809000-00029] [PMID: 9754124] 
[97] 
Tateishi U, Kusumoto M, Hasegawa T, Yokoyama R, Moriyama N. Primary malignant fibrous histiocytoma of the chest wall: CT and MR appearance. J Comput Assist Tomogr  2002; 26(4): 558-63.
[http://dx.doi.org/10.1097/00004728-200207000-00015] [PMID: 12218820] 
[98] 
Kaya M, Wada T, Nagoya S, et al. MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol  2008; 37(12): 1085-90.
[http://dx.doi.org/10.1007/s00256-008-0542-4] [PMID: 18629459] 
[99] 
Waters B, Panicek DM, Lefkowitz RA, et al. Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol  2007; 188(2): W193-8.
[http://dx.doi.org/10.2214/AJR.05.1130] [PMID: 17242227] 
[100] 
Mansoor A, White CR Jr. Myxofibrosarcoma presenting in the skin: clinicopathological features and differential diagnosis with cutaneous myxoid neoplasms. Am J Dermatopathol  2003; 25(4): 281-6.
[http://dx.doi.org/10.1097/00000372-200308000-00001] [PMID: 12876484] 
[101] 
Lefkowitz RA, Landa J, Hwang S, et al. Myxofibrosarcoma: prevalence and diagnostic value of the “tail sign” on magnetic resonance imaging. Skeletal Radiol  2013; 42(6): 809-18.
[http://dx.doi.org/10.1007/s00256-012-1563-6] [PMID: 23318907] 
[102] 
White LM, Wunder JS, Bell RS, et al. Histologic assessment of peritumoral edema in soft tissue sarcoma. Int J Radiat Oncol Biol Phys  2005; 61(5): 1439-45.
[http://dx.doi.org/10.1016/j.ijrobp.2004.08.036] [PMID: 15817348] 
[103] 
Iwata S, Araki A, Funatsu H, et al. Optimal surgical margin for infiltrative soft tissue sarcomas: Assessing the efficacy of excising beyond the infiltration. J Surg Oncol  2018; 118(3): 525-31.
[PMID: 30259517] 
[104] 
Kikuta K, Kubota D, Yoshida A, et al. An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol  2013; 43(11): 1093-104.
[http://dx.doi.org/10.1093/jjco/hyt119] [PMID: 23969617] 
[105] 
Iwata S, Yonemoto T, Araki A, et al. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol  2014; 110(6): 707-11.
[http://dx.doi.org/10.1002/jso.23708] [PMID: 24975462] 
[106] 
van Vliet M, Kliffen M, Krestin GP, van Dijke CF. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol  2009; 19(6): 1499-511.
[http://dx.doi.org/10.1007/s00330-008-1292-3] [PMID: 19266204] 
[107] 
Mankin HJ, Casas-Ganem J, Kim J-I, Gebhardt MC, Hornicek FJ, Zeegen EN. Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res  2004; (421): 225-31.
[http://dx.doi.org/10.1097/01.blo.0000119250.08614.82] [PMID: 15123952] 
[108] 
Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol  2008; 97(4): 314-20.
[http://dx.doi.org/10.1002/jso.20974] [PMID: 18286474] 
[109] 
Baheti AD, Tirumani SH, Sewatkar R, et al. Imaging features of primary and metastatic extremity synovial sarcoma: a single institute experience of 78 patients. Br J Radiol  2015; 88(1046): 20140608.
[http://dx.doi.org/10.1259/bjr.20140608] [PMID: 25431890] 
[110] 
Murphey MD, Gibson MS, Jennings BT, Crespo-Rodríguez AM, Fanburg-Smith J, Gajewski DA. From the archives of the AFIP: Imaging of synovial sarcoma with radiologic-pathologic correlation. Radiographics  2006; 26(5): 1543-65.
[http://dx.doi.org/10.1148/rg.265065084] [PMID: 16973781] 
[111] 
Bixby SD, Hettmer S, Taylor GA, Voss SD. Synovial sarcoma in children: Imaging features and common benign mimics. AJR Am J Roentgenol  2010; 195(4): 1026-32.
[http://dx.doi.org/10.2214/AJR.10.4348] [PMID: 20858835] 
[112] 
Tateishi U, Hasegawa T, Beppu Y, Satake M, Moriyama N. Synovial sarcoma of the soft tissues: Prognostic significance of imaging features. J Comput Assist Tomogr  2004; 28(1): 140-8.
[http://dx.doi.org/10.1097/00004728-200401000-00024] [PMID: 14716248] 
[113] 
Buck P, Mickelson MR, Bonfiglio M. Synovial sarcoma: A review of 33 cases. Clin Orthop Relat Res  1981; (156): 211-5.
[http://dx.doi.org/10.1097/00003086-198105000-00031] [PMID: 6164515] 
[114] 
Ferrari A, De Salvo GL, Dall’Igna P, et al. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. Eur J Cancer  2012; 48(18): 3448-55.
[http://dx.doi.org/10.1016/j.ejca.2012.06.017] [PMID: 22835783] 
[115] 
Ryan JR, Baker LH, Benjamin RS. The natural history of metastatic synovial sarcoma: Experience of the Southwest Oncology group. Clin Orthop Relat Res  1982; (164): 257-60.
[http://dx.doi.org/10.1097/00003086-198204000-00046] [PMID: 6279348] 
[116] 
Salah S, Salem A. Primary synovial sarcomas of the mediastinum: A systematic review and pooled analysis of the published literature. ISRN Oncol  2014; 2014: 412527.
[http://dx.doi.org/10.1155/2014/412527] [PMID: 24563786] 
[117] 
Lisle JW, Eary JF, O’Sullivan J, Conrad EU. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin Orthop Relat Res  2009; 467(6): 1605-11.
[http://dx.doi.org/10.1007/s11999-008-0647-z] [PMID: 19048352] 
[118] 
Kamran SC, Shinagare AB, Howard SA, Hornick JL, Ramaiya NH. A-Z of malignant peripheral nerve sheath tumors. Cancer Imaging  2012; 12: 475-83.
[http://dx.doi.org/10.1102/1470-7330.2012.0043] [PMID: 23108260] 
[119] 
Hrehorovich PA, Franke HR, Maximin S, Caracta P. Malignant peripheral nerve sheath tumor. Radiographics  2003; 23(3): 790-4.
[http://dx.doi.org/10.1148/rg.233025153] [PMID: 12740477] 
[120] 
Van Herendael BH, Heyman SRG, Vanhoenacker FM, et al. The value of magnetic resonance imaging in the differentiation between malignant peripheral nerve-sheath tumors and non-neurogenic malignant soft-tissue tumors. Skeletal Radiol  2006; 35(10): 745-53.
[http://dx.doi.org/10.1007/s00256-006-0160-y] [PMID: 16775712] 
[121] 
Wasa J, Nishida Y, Tsukushi S, et al. MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol  2010; 194(6): 1568-74.
[http://dx.doi.org/10.2214/AJR.09.2724] [PMID: 20489098] 
[122] 
Brenner W, Friedrich RE, Gawad KA, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging  2006; 33(4): 428-32.
[http://dx.doi.org/10.1007/s00259-005-0030-1] [PMID: 16404595] 
[123] 
Khiewvan B, Macapinlac HA, Lev D, et al. The value of 18F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging  2014; 41(9): 1756-66.
[http://dx.doi.org/10.1007/s00259-014-2756-0] [PMID: 24699907] 
[124] 
Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer  2010; 116(2): 451-8.
[http://dx.doi.org/10.1002/cncr.24755] [PMID: 19924789] 
[125] 
Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol  2008; 19(2): 390-4.
[http://dx.doi.org/10.1093/annonc/mdm450] [PMID: 17932395] 
[126] 
Demehri S, Belzberg A, Blakeley J, Fayad LM. Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR Am J Neuroradiol  2014; 35(8): 1615-20.
[http://dx.doi.org/10.3174/ajnr.A3910] [PMID: 24763412] 
[127] 
Van Rijn RR, Wilde JCH, Bras J, Oldenburger F, McHugh KMC, Merks JHM. Imaging findings in noncraniofacial childhood rhabdomyosarcoma. Pediatr Radiol  2008; 38(6): 617-34.
[http://dx.doi.org/10.1007/s00247-008-0751-y] [PMID: 18324394] 
[128] 
Pai DR, Ladino-Torres MF. Magnetic resonance imaging of pediatric pelvic masses. Magn Reson Imaging Clin N Am  2013; 21(4): 751-72.
[http://dx.doi.org/10.1016/j.mric.2013.07.002] [PMID: 24183524] 
[129] 
Stein-Wexler R. MR imaging of soft tissue masses in children. Magn Reson Imaging Clin N Am  2009; 17(3): 489-507.
[http://dx.doi.org/10.1016/j.mric.2009.03.009] [PMID: 19524198] 
[130] 
Paoluzzi L, Maki RG. Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: A review. JAMA Oncol  2019; 5(2): 254-60.
[http://dx.doi.org/10.1001/jamaoncol.2018.4490] 
[131] 
McCarville MB, Muzzafar S, Kao SC, et al. Imaging features of alveolar soft-part sarcoma: A report from Children’s Oncology Group Study ARST0332. AJR Am J Roentgenol  2014; 203(6): 1345-52.
[http://dx.doi.org/10.2214/AJR.14.12462] [PMID: 25415714] 
[132] 
Kim HS, Lee HK, Weon Y-C, Kim H-J. Alveolar soft-part sarcoma of the head and neck: Clinical and imaging features in five cases. AJNR Am J Neuroradiol  2005; 26(6): 1331-5.
[PMID: 15956492] 
[133] 
Viry F, Orbach D, Klijanienko J, et al. Alveolar soft part sarcoma-radiologic patterns in children and adolescents. Pediatr Radiol  2013; 43(9): 1174-81.
[http://dx.doi.org/10.1007/s00247-013-2667-4] [PMID: 23681452] 
[134] 
Suh JS, Cho J, Lee SH, et al. Alveolar soft part sarcoma: MR and angiographic findings. Skeletal Radiol  2000; 29(12): 680-9.
[http://dx.doi.org/10.1007/s002560000285] [PMID: 11271548] 
[135] 
Iwamoto Y, Morimoto N, Chuman H, Shinohara N, Sugioka Y. The role of MR imaging in the diagnosis of alveolar soft part sarcoma: a report of 10 cases. Skeletal Radiol  1995; 24(4): 267-70.
[http://dx.doi.org/10.1007/BF00198412] [PMID: 7644939] 
[136] 
Stein-Wexler R. Pediatric soft tissue sarcomas. Semin Ultrasound CT MR  2011; 32(5): 470-88.
[http://dx.doi.org/10.1053/j.sult.2011.03.006] [PMID: 21963167] 
[137] 
Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol  1995; 164(1): 129-34.
[http://dx.doi.org/10.2214/ajr.164.1.7998525] [PMID: 7998525] 
[138] 
ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol  2014; 25(Suppl. 3): iii102-12.
[http://dx.doi.org/10.1093/annonc/mdu254] [PMID: 25210080] 
[139] 
Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft-tissue sarcoma: Preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology  2007; 245(3): 839-47.
[http://dx.doi.org/10.1148/radiol.2453061538] [PMID: 18024454] 
[140] 
Roberge D, Vakilian S, Alabed YZ, Turcotte RE, Freeman CR, Hickeson M. FDG PET/CT in initial staging of adult soft-tissue sarcoma. Sarcoma  2012; 2012: 960194.
[http://dx.doi.org/10.1155/2012/960194] [PMID: 23251096] 
[141] 
Völker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: Results of a prospective multicenter trial. J Clin Oncol  2007; 25(34): 5435-41.
[http://dx.doi.org/10.1200/JCO.2007.12.2473] [PMID: 18048826] 
[142] 
Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol  2011; 21(12): 2604-17.
[http://dx.doi.org/10.1007/s00330-011-2221-4] [PMID: 21887484] 
[143] 
Eugene T, Corradini N, Carlier T, Dupas B, Leux C, Bodet-Milin C. 18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nucl Med Commun  2012; 33(10): 1089-95.
[http://dx.doi.org/10.1097/MNM.0b013e328356741f] [PMID: 22929116] 
[144] 
Miki Y, Ngan S, Clark JCM, Akiyama T, Choong PFM. The significance of size change of soft tissue sarcoma during preoperative radiotherapy. Eur J Surg Oncol  2010; 36(7): 678-83.
[http://dx.doi.org/10.1016/j.ejso.2010.05.021] [PMID: 20547446] 
[145] 
Look Hong NJ, Hornicek FJ, Harmon DC, et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer  2013; 49(4): 875-83.
[http://dx.doi.org/10.1016/j.ejca.2012.10.002] [PMID: 23092789] 
[146] 
le Grange F, Cassoni AM, Seddon BM. Tumour volume changes following pre-operative radiotherapy in borderline resectable limb and trunk soft tissue sarcoma. Eur J Surg Oncol  2014; 40(4): 394-401.
[http://dx.doi.org/10.1016/j.ejso.2014.01.011] [PMID: 24534361] 
[147] 
Roberge D, Skamene T, Nahal A, Turcotte RE, Powell T, Freeman C. Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother Oncol  2010; 97(3): 404-7.
[http://dx.doi.org/10.1016/j.radonc.2010.10.007] [PMID: 21040989] 
[148] 
Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res  2008; 14(3): 715-20.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-1762] [PMID: 18245531] 
[149] 
Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer  2005; 103(2): 339-48.
[http://dx.doi.org/10.1002/cncr.20769] [PMID: 15578712] 
[150] 
Benz MR, Evilevitch V, Allen-Auerbach MS, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med  2008; 49(7): 1038-46.
[http://dx.doi.org/10.2967/jnumed.107.050187] [PMID: 18552153] 
[151] 
Eary JF, Conrad EU, O’Sullivan J, Hawkins DS, Schuetze SM, O’Sullivan F. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. J Bone Joint Surg Am  2014; 96(2): 152-8.
[http://dx.doi.org/10.2106/JBJS.M.00062] [PMID: 24430415] 
[152] 
Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: Tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology  2009; 251(2): 447-56.
[http://dx.doi.org/10.1148/radiol.2512081403] [PMID: 19261927] 
[153] 
Stacchiotti S, Verderio P, Messina A, et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer  2012; 118(23): 5857-66.
[http://dx.doi.org/10.1002/cncr.27624] [PMID: 22605504] 
[154] 
Fayad LM, Jacobs MA, Wang X, Carrino JA, Bluemke DA. Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques. Radiology  2012; 265(2): 340-56.
[http://dx.doi.org/10.1148/radiol.12111740] [PMID: 23093707] 
[155] 
Landa J, Schwartz LH. Contemporary imaging in sarcoma. Oncologist  2009; 14(10): 1021-38.
[http://dx.doi.org/10.1634/theoncologist.2009-0194] [PMID: 19789392] 
[156] 
Meyer JM, Perlewitz KS, Hayden JB, et al. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res  2013; 19(24): 6902-11.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1594] [PMID: 24132922] 
[157] 
Hain SF, O’Doherty MJ, Bingham J, Chinyama C, Smith MA. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl Med Commun  2003; 24(11): 1139-43.
[http://dx.doi.org/10.1097/00006231-200311000-00003] [PMID: 14569167] 
[158] 
Tavare AN, Robinson P, Altoos R, et al. Postoperative imaging of sarcomas. AJR Am J Roentgenol  2018; 211(3): 506-18.
[http://dx.doi.org/10.2214/AJR.18.19954] [PMID: 29927329] 
[159] 
Holzapfel K, Regler J, Baum T, et al. Local staging of soft-tissue sarcoma: emphasis on assessment of neurovascular encasement-value of MR imaging in 174 confirmed cases. Radiology  2015; 275(2): 501-9.
[http://dx.doi.org/10.1148/radiol.14140510] [PMID: 25584707] 
[160] 
Panicek DM, Go SD, Healey JH, Leung DH, Brennan MF, Lewis JJ. Soft-tissue sarcoma involving bone or neurovascular structures: MR imaging prognostic factors. Radiology  1997; 205(3): 871-5.
[http://dx.doi.org/10.1148/radiology.205.3.9393550] [PMID: 9393550] 
[161] 
Robinson E, Bleakney RR, Ferguson PC, O’Sullivan B. Oncodiagnosis panel: 2007: multidisciplinary management of soft-tissue sarcoma. Radiographics  2008; 28(7): 2069-86.
[http://dx.doi.org/10.1148/rg.287085167] [PMID: 19001660] 
[162] 
Feydy A, Anract P, Tomeno B, Chevrot A, Drapé J-L. Assessment of vascular invasion by musculoskeletal tumors of the limbs: use of contrast-enhanced MR angiography. Radiology  2006; 238(2): 611-21.
[http://dx.doi.org/10.1148/radiol.2382041725] [PMID: 16436820] 
[163] 
Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the radiology diagnostic oncology group. Radiology  1997; 202(1): 237-46.
[http://dx.doi.org/10.1148/radiology.202.1.8988217] [PMID: 8988217] 
[164] 
Schwarzbach MHM, Hormann Y, Hinz U, et al. Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity. J Vasc Surg  2005; 42(1): 88-97.
[http://dx.doi.org/10.1016/j.jvs.2005.03.017] [PMID: 16012457] 
[165] 
Ferguson PC, Griffin AM, O’Sullivan B, et al. Bone invasion in extremity soft-tissue sarcoma: Impact on disease outcomes. Cancer  2006; 106(12): 2692-700.
[http://dx.doi.org/10.1002/cncr.21949] [PMID: 16700041] 
[166] 
Elias DA, White LM, Simpson DJ, et al. Osseous invasion by soft-tissue sarcoma: assessment with MR imaging. Radiology  2003; 229(1): 145-52.
[http://dx.doi.org/10.1148/radiol.2291020377] [PMID: 14519874] 
[167] 
Hong JH, Jee W-H, Jung C-K, Jung J-Y, Shin SH, Chung Y-G. Soft tissue sarcoma: adding diffusion-weighted imaging improves MR imaging evaluation of tumor margin infiltration. Eur Radiol  2019; 29(5): 2589-97.
[http://dx.doi.org/10.1007/s00330-018-5817-0] [PMID: 30413958] 
[168] 
Wang L, Pretell-Mazzini J, Kerr DA, et al. MRI findings associated with microscopic residual tumor following unplanned excision of soft tissue sarcomas in the extremities. Skeletal Radiol  2018; 47(2): 181-90.
[http://dx.doi.org/10.1007/s00256-017-2762-y] [PMID: 28864832] 
[169] 
Davies AM, Mehr A, Parsonage S, Evans N, Grimer RJ, Pynsent PB. MR imaging in the assessment of residual tumour following inadequate primary excision of soft tissue sarcomas. Eur Radiol  2004; 14(3): 506-13.
[http://dx.doi.org/10.1007/s00330-003-2023-4] [PMID: 14557894] 
[170] 
Puhaindran ME, Pratt J, Manoso MW, Healey JH, Mintz DN, Athanasian EA. Predictive value of magnetic resonance imaging in determining presence of residual disease after marginal excision of unsuspected soft tissue sarcomas of the hand. J Hand Surg Am  2010; 35(9): 1479-84.
[http://dx.doi.org/10.1016/j.jhsa.2010.05.009] [PMID: 20807625] 
[171] 
Gingrich AA, Elias A, Michael Lee C-Y, et al. Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res  2017; 208: 26-32.
[http://dx.doi.org/10.1016/j.jss.2016.08.096] [PMID: 27993214] 
[172] 
Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multimodal imaging: PET/CT compared with Pet alone in staging and follow-up of patients with Ewing tumors. J Nucl Med  2007; 48(12): 1932-9.
[http://dx.doi.org/10.2967/jnumed.107.045286] [PMID: 18006618] 
[173] 
McCarville MB. PET-CT imaging in pediatric oncology. Cancer Imaging  2009; 9: 35-43.
[http://dx.doi.org/10.1102/1470-7330.2009.0008] [PMID: 19602470] 
[174] 
Cheney MD, Giraud C, Goldberg SI, et al. MRI surveillance following treatment of extremity soft tissue sarcoma. J Surg Oncol  2014; 109(6): 593-6.
[http://dx.doi.org/10.1002/jso.23541] [PMID: 24374823] 
[175] 
Labarre D, Aziza R, Filleron T, et al. Detection of local recurrences of limb soft tissue sarcomas: Is magnetic resonance imaging (MRI) relevant? Eur J Radiol  2009; 72(1): 50-3.
[http://dx.doi.org/10.1016/j.ejrad.2009.05.027] [PMID: 19744809] 
[176] 
Del Grande F, Subhawong T, Weber K, Aro M, Mugera C, Fayad LM. Detection of soft-tissue sarcoma recurrence: Added value of functional MR imaging techniques at 3.0 T. Radiology  2014; 271(2): 499-511.
[http://dx.doi.org/10.1148/radiol.13130844] [PMID: 24495264] 
[177] 
Vanel D, Lacombe MJ, Couanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: Follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology  1987; 164(1): 243-5.
[http://dx.doi.org/10.1148/radiology.164.1.3588913] [PMID: 3588913] 
[178] 
Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: Results of 511 examinations. Radiology  1994; 190(1): 263-8.
[http://dx.doi.org/10.1148/radiology.190.1.8259417] [PMID: 8259417] 
[179] 
Chou SS, Hippe DS, Lee AY, et al. Gadolinium contrast enhancement improves confidence in diagnosing recurrent soft tissue sarcoma by MRI. Acad Radiol  2017; 24(5): 615-22.
[http://dx.doi.org/10.1016/j.acra.2016.12.010] [PMID: 28117119] 
[180] 
Garner HW, Kransdorf MJ. Musculoskeletal sarcoma: update on imaging of the post-treatment patient. Can Assoc Radiol J  2016; 67(1): 12-20.
[http://dx.doi.org/10.1016/j.carj.2014.11.002] [PMID: 25660298] 
[181] 
Garner HW, Kransdorf MJ, Bancroft LW, Peterson JJ, Berquist TH, Murphey MD. Benign and malignant soft-tissue tumors: Posttreatment MR imaging. Radiographics  2009; 29(1): 119-34.
[http://dx.doi.org/10.1148/rg.291085131] [PMID: 19168840] 
[182] 
Piperkova E, Mikhaeil M, Mousavi A, et al. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin Nucl Med  2009; 34(3): 146-50.
[http://dx.doi.org/10.1097/RLU.0b013e3181966f9d] [PMID: 19352275] 
[183] 
Byun BH, Kim SH, Lim SM, et al. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT. Eur Radiol  2015; 25(7): 2015-24.
[http://dx.doi.org/10.1007/s00330-015-3609-3] [PMID: 25680716] 
[184] 
Fuglø HM, Jørgensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging  2012; 39(9): 1416-24.
[http://dx.doi.org/10.1007/s00259-012-2159-z] [PMID: 22699526] 
[185] 
Al-Ibraheem A, Buck AK, Benz MR, et al. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer  2013; 119(6): 1227-34.
[http://dx.doi.org/10.1002/cncr.27866] [PMID: 23233156] 
[186] 
King DM, Hackbarth DA, Kilian CM, Carrera GF. Soft-tissue sarcoma metastases identified on abdomen and pelvis CT imaging. Clin Orthop Relat Res  2009; 467(11): 2838-44.
[http://dx.doi.org/10.1007/s11999-009-0989-1] [PMID: 19636646] 
[187] 
Cheng EY, Springfield DS, Mankin HJ. Frequent incidence of extrapulmonary sites of initial metastasis in patients with liposarcoma. Cancer  1995; 75(5): 1120-7.
[http://dx.doi.org/10.1002/1097-0142(19950301)75:5<1120::AID-CNCR2820750511>3.0.CO;2-7] [PMID: 7850710] 
[188] 
Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg  1987; 205(4): 349-59.
[http://dx.doi.org/10.1097/00000658-198704000-00003] [PMID: 3566372] 
[189] 
Zanarini D, Sugarbaker PH. Extremity soft tissue sarcoma with metastases to abdominopelvic surfaces. J Surg Oncol  1997; 64(1): 68-72.
[http://dx.doi.org/10.1002/(SICI)1096-9098(199701)64:1<68::AID-JSO13>3.0.CO;2-S] [PMID: 9040804] 
[190] 
Thompson MJ, Ross J, Domson G, Foster W. Screening and surveillance CT abdomen/pelvis for metastases in patients with soft-tissue sarcoma of the extremity. Bone Joint Res  2015; 4(3): 45-9.
[http://dx.doi.org/10.1302/2046-3758.43.2000337] [PMID: 25792705] 
[191] 
Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer  1999; 85(2): 389-95.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19990115)85:2<389::AID-CNCR17>3.0.CO;2-J] [PMID: 10023707] 
[192] 
Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol  1996; 14(5): 1679-89.
[http://dx.doi.org/10.1200/JCO.1996.14.5.1679] [PMID: 8622088] 
[193] 
Haaga JR. Radiation dose management: Weighing risk versus benefit. AJR Am J Roentgenol  2001; 177(2): 289-91.
[http://dx.doi.org/10.2214/ajr.177.2.1770289] [PMID: 11461847] 
[194] 
Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med  2005; 353(7): 701-11.
[http://dx.doi.org/10.1056/NEJMra041866] [PMID: 16107623] 
[195] 
Kane JM III. Surveillance strategies for patients following surgical resection of soft tissue sarcomas. Curr Opin Oncol  2004; 16(4): 328-32.
[http://dx.doi.org/10.1097/01.cco.0000127879.62254.d3] [PMID: 15187887] 
[196] 
Merchant MS, Mackall CL. Current approach to pediatric soft tissue sarcomas. Oncologist  2009; 14(11): 1139-53.
[http://dx.doi.org/10.1634/theoncologist.2009-0160] [PMID: 19897537] 
[197] 
Rodeberg DA, Garcia-Henriquez N, Lyden ER, et al. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: A report from the Children’s Oncology Group. J Clin Oncol  2011; 29(10): 1304-11.
[http://dx.doi.org/10.1200/JCO.2010.29.4611] [PMID: 21357792] 
[198] 
Meza JL, Anderson J, Pappo AS, Meyer WH. Children’s Oncology Group. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children’s Oncology Group. J Clin Oncol  2006; 24(24): 3844-51.
[http://dx.doi.org/10.1200/JCO.2005.05.3801] [PMID: 16921036] 
[199] 
Sherman KL, Kinnier CV, Farina DA, et al. Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma. J Surg Oncol  2014; 110(6): 682-8.
[http://dx.doi.org/10.1002/jso.23687] [PMID: 24910401] 
[200] 
Sawamura C, Matsumoto S, Shimoji T, Ae K, Okawa A. Lymphadenectomy and histologic subtype affect overall survival of soft tissue sarcoma patients with nodal metastases. Clin Orthop Relat Res  2013; 471(3): 926-31.
[http://dx.doi.org/10.1007/s11999-012-2568-0] [PMID: 22956238] 
[201] 
La TH, Wolden SL, Rodeberg DA, et al. Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: A report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys  2011; 80(4): 1151-7.
[http://dx.doi.org/10.1016/j.ijrobp.2010.03.050] [PMID: 20542386] 
[202] 
Andrassy RJ, Okcu MF, Despa S, Raney RB. Synovial sarcoma in children: Surgical lessons from a single institution and review of the literature. J Am Coll Surg  2001; 192(3): 305-13.
[http://dx.doi.org/10.1016/S1072-7515(00)00806-1] [PMID: 11245372] 
[203] 
Neville HL, Andrassy RJ, Lobe TE, et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Pediatr Surg  2000; 35(2): 317-21.
[http://dx.doi.org/10.1016/S0022-3468(00)90031-9] [PMID: 10693687] 
[204] 
Wright S, Armeson K, Hill eg, et al. The role of sentinel lymph node biopsy in select sarcoma patients: A meta-analysis. Am J Surg  2012; 204(4): 428-33.
[http://dx.doi.org/10.1016/j.amjsurg.2011.12.019] [PMID: 22578407] 
[205] 
Terwisscha van Scheltinga CEJ, Spronk P, van Rosmalen J, et al. Diagnosis and treatment of lymph node metastases in pediatric rhabdomyosarcoma in the Netherlands: A retrospective analysis. J Pediatr Surg  2014; 49(3): 416-9.
[http://dx.doi.org/10.1016/j.jpedsurg.2013.08.002] [PMID: 24650468] 
[206] 
Wagner LM, Kremer N, Gelfand MJ, et al. Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging-A prospective trial. Cancer  2017; 123(1): 155-60.
[http://dx.doi.org/10.1002/cncr.30282] [PMID: 27563842] 
[207] 
Sala E, Mema E, Himoto Y, et al. Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol  2017; 72(1): 3-10.
[http://dx.doi.org/10.1016/j.crad.2016.09.013] [PMID: 27742105] 
[208] 
Behzadi AH, Raza SI, Carrino JA, et al. Applications of PET/CT and PET/MR imaging in primary bone malignancies. PET Clin  2018; 13(4): 623-34.
[http://dx.doi.org/10.1016/j.cpet.2018.05.012] [PMID: 30219192] 
Cite As
Current Medical Imaging

Imaging of Soft Tissue Tumors

Abstract

Graphical Abstract
